Figure 3
BC-PDE cell death responses to FET chemotherapy. 46 BC-PDEs were treated with FET and a combined value of fold change of drug-induced tumour apoptosis/necrosis compared to vehicle control was calculated for each patient sample. (A) BC-PDEs were classified into high (H), medium (M), or low (L) drug-induced apoptosis/necrosis where H = > 5, M = > 2.5 and L = < 2.5-fold change. † indicates PDEs from patients that have subsequently died and ° indicates PDEs from patients that have had a recurrence (Additional File 1). (B) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) compared to control according to tumour grade. (C) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) compared to control according to tumour stage. (D) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) compared to control according to tumour histological subtype. (E) Fold change in drug-induced apoptosis (left) or combined apoptosis/necrosis (right) compared to control according to tumour molecular subtype. Statistics were performed using the Mann–Whitney test where p < 0.05 are shown. Values displayed above each group represent the number of patient samples in each group.
